Basit öğe kaydını göster

dc.contributor.authorBeksac, Meral
dc.contributor.authorSeval, Guldane Cengiz
dc.contributor.authorPaydas, Semra
dc.contributor.authorTuglular, Tulin Firatli
dc.contributor.authorArslan, Onder
dc.contributor.authorGoker, Hakan
dc.contributor.authorKaynar, Leylagul
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorAtalay, Figen
dc.contributor.authorTeke, Havva Uskudar
dc.contributor.authorBolaman, Ali Zahit
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorSonmez, Mehmet
dc.contributor.authorDemir, Ahmet Muzaffer
dc.contributor.authorTopcuoglu, Pervin
dc.contributor.authorYilmaz, Mehmet
dc.contributor.authorKabukcu, Sibel Hacioglu
dc.contributor.authorAlbayrak, Murat
dc.contributor.authorYurttas, Nurgul Ozer
dc.contributor.authorSalihoglu, Ayse
dc.contributor.authorCakar, Merih Kizil
dc.contributor.authorGurman, Gunhan
dc.date.accessioned2020-10-23T08:16:02Z
dc.date.available2020-10-23T08:16:02Z
dc.date.issued2019
dc.identifier.issn2152-2650en_US
dc.identifier.urihttp://hdl.handle.net/11727/4957
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.clml.2019.09.402en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectelotuzumaben_US
dc.subjectimmunomodulatory drugsen_US
dc.subjectMultiple myelomaen_US
dc.titleElotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkeyen_US
dc.typeconferenceObjecten_US
dc.relation.journalCLINICAL LYMPHOMA MYELOMA & LEUKEMIAen_US
dc.identifier.volume19en_US
dc.identifier.issue10en_US
dc.identifier.startpageE242en_US
dc.identifier.endpageE243en_US
dc.identifier.wos000491229800399en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster